

György Bodoky

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5104906/publications.pdf>

Version: 2024-02-01

99
papers

26,299
citations

53794

45
h-index

39675

94
g-index

104
all docs

104
docs citations

104
times ranked

24080
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Response and Symptom Palliation from RAINBOW , a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer. <i>Oncologist</i> , 2021, 26, e414-e424.	3.7	4
2	Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). <i>Journal of Clinical Oncology</i> , 2021, 39, 990-1000.	1.6	30
3	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	10.7	337
4	Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 62-75.	1.1	22
5	Current therapy of advanced colorectal cancer according to RAS/RAF mutational status. <i>Cancer and Metastasis Reviews</i> , 2020, 39, 1143-1157.	5.9	19
6	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. <i>ESMO Open</i> , 2020, 5, e000662.	4.5	15
7	Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group. <i>Annals of Oncology</i> , 2020, 31, 246-256.	1.2	20
8	Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2201-2207.	1.9	4
9	Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 420-435.	10.7	191
10	Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465.	8.1	36
11	Expenditures on Oncology Drugs and Cancer Mortality-to-Incidence Ratio in Central and Eastern Europe. <i>Oncologist</i> , 2019, 24, e30-e37.	3.7	19
12	Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591881835.	3.2	13
13	Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISEâ€”a global phase III study. <i>Annals of Oncology</i> , 2019, 30, 124-131.	1.2	52
14	Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results. <i>Pathology and Oncology Research</i> , 2019, 25, 149-156.	1.9	4
15	Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study. <i>Annals of Oncology</i> , 2018, 29, 602-609.	1.2	83
16	Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set. <i>ESMO Open</i> , 2018, 3, e000347.	4.5	15
17	Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. <i>Journal of Hepatology</i> , 2018, 69, 353-358.	3.7	270
18	Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 814-824.	2.8	18

#	ARTICLE	IF	CITATIONS
19	Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). <i>European Journal of Cancer</i> , 2018, 89, 82-89.	2.8	16
20	The effect of best response to prior anticancer therapy on efficacy outcomes in the NAPOLI-1 trial of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy. <i>Annals of Oncology</i> , 2018, 29, v42.	1.2	0
21	Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience.. <i>Pathology and Oncology Research</i> , 2017, 23, 753-759.	1.9	20
22	Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 56-66.	13.7	2,771
23	Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. <i>Lancet Oncology, The</i> , 2017, 18, 640-653.	10.7	383
24	Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer. <i>Annals of Oncology</i> , 2017, 28, 354-361.	1.2	50
25	Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 2215-2222.	4.1	41
26	Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 599-608.	2.3	18
27	Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data. <i>Journal of Gastric Cancer</i> , 2017, 17, 132.	2.5	54
28	Subgroup analysis by prior non-liposomal irinotecan therapy in NAPOLI-1: a phase 3 study of nal-IRI±5-fluorouracil/leucovorin in patients with metastatic pancreatic ductal adenocarcinoma previously treated with gemcitabine-based therapy. <i>Annals of Oncology</i> , 2017, 28, x67-x68.	1.2	0
29	Analysis of angiogenesis biomarkers for ramucirumab (RAM) efficacy in patients with metastatic colorectal cancer (mCRC) from RAISE, a global, randomized, double-blind, Phase 3 study. <i>Annals of Oncology</i> , 2017, 28, v188-v189.	1.2	4
30	PD-024 Retrospective analysis of quality of life and early tumour shrinkage during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 2016, 27, ii110.	1.2	0
31	PD-029 Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCRC) phase 3 trial. <i>Annals of Oncology</i> , 2016, 27, ii113.	1.2	0
32	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	1.2	2,545
33	Exposure-response (E-R) relationship of Ramucirumab (RAM) from a global, randomized, double-blind, Phase 3 study of patients (Pts) with advanced 2nd line colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, iv40.	1.2	1
34	Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression. <i>Annals of Oncology</i> , 2016, 27, 2082-2089.	1.2	56
35	Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. <i>ESMO Open</i> , 2016, 1, e000041.	4.5	15
36	Cancer Control in Central and Eastern Europe: Current Situation and Recommendations for Improvement. <i>Oncologist</i> , 2016, 21, 1183-1190.	3.7	37

#	ARTICLE	IF	CITATIONS
37	Is neutropenia a prognostic or a predictive factor for second line metastatic colorectal cancer (mCRC) patients (Pts)? Exploratory analysis from RAISE, a randomized, double-blind, phase III study of ramucirumab (RAM) + FOLFIRI vs placebo (PBO) + FOLFIRI. <i>Annals of Oncology</i> , 2016, 27, vi198.	1.2	1
38	Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). <i>Annals of Oncology</i> , 2016, 27, 856-861.	1.2	107
39	Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma. <i>Annals of Oncology</i> , 2016, 27, 673-679.	1.2	62
40	Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2016, 387, 545-557.	13.7	878
41	A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. <i>Annals of Oncology</i> , 2015, 26, 921-927.	1.2	132
42	Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 109-117.	1.3	15
43	Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. <i>Lancet Oncology, The</i> , 2015, 16, 499-508.	10.7	753
44	Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562.	2.4	13
45	Analysis of European Patients Enrolled in a Global Early Access Protocol with Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer Progressing After Chemotherapy. <i>Annals of Oncology</i> , 2014, 25, iv269.	1.2	1
46	Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. <i>Annals of Oncology</i> , 2014, 25, 1346-1355.	1.2	462
47	Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2014, 15, 1224-1235.	10.7	1,932
48	Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 547-555.	2.5	45
49	Clinical Benefit Response in Pancreatic Cancer Trials Revisited. <i>Oncology Research and Treatment</i> , 2014, 37, 1-1.	1.2	14
50	Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. <i>European Journal of Cancer</i> , 2013, 49, 3616-3624.	2.8	78
51	Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. <i>Annals of Oncology</i> , 2013, 24, 718-725.	1.2	81
52	Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. <i>Lancet Oncology, The</i> , 2013, 14, 490-499.	10.7	740
53	Panitumumab and FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 1023-1034.	27.0	1,971
54	Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. <i>Annals of Oncology</i> , 2013, 24, 710-718.	1.2	57

#	ARTICLE	IF	CITATIONS
55	Evaluation of KRAS, NRAS, and BRAF Mutations in Prime: Panitumumab with FOLFOX4 as First-Line Treatment in Metastatic Colorectal Cancer (MCR). <i>Annals of Oncology</i> , 2013, 24, iv23-iv24.	1.2	0
56	Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. <i>Annals of Oncology</i> , 2012, 23, 1214-1222.	1.2	91
57	Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 1225-1233.	10.7	484
58	ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. <i>Annals of Oncology</i> , 2012, 23, 2479-2516.	1.2	1,233
59	Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III). <i>Journal of Clinical Oncology</i> , 2012, 30, 3588-3595.	1.6	194
60	P-0073 GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its Treatment) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5	1.2	0
61	Non Inferiority Analysis of Multicenter Phase III Comparing Cisplatin/S-1 (CS) with Cisplatin/5-Fu (CF) as First-Line Therapy in Patients with advanced Gastric Cancer (FLAGS): Methodology and Results. <i>Annals of Oncology</i> , 2012, 23, ix224-ix225.	1.2	4
62	A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5 have failed first-line gemcitabine therapy. <i>Investigational New Drugs</i> , 2012, 30, 1216-1223.	2.6	196
63	Tricellulin expression in normal and neoplastic human pancreas. <i>Histopathology</i> , 2012, 60, E76-86.	2.9	42
64	Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1997-2003.	1.6	161
65	The Activated Targets of mTOR Signaling Pathway Are Characteristic for PDGFRA Mutant and Wild-type Rather Than KIT Mutant GISTs. <i>Diagnostic Molecular Pathology</i> , 2011, 20, 22-33.	2.1	23
66	Cancer epidemiology in Central and South Eastern European countries. <i>Croatian Medical Journal</i> , 2011, 52, 478-487.	0.7	53
67	Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. <i>British Journal of Cancer</i> , 2010, 103, 1318-1324.	6.4	33
68	Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06). <i>Oncologist</i> , 2010, 15, 285-292.	3.7	93
69	Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 1547-1553.	1.6	498
70	Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4697-4705.	1.6	1,644
71	Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial. <i>Journal of Clinical Oncology</i> , 2010, 28, 466-474.	1.6	1,048
72	Randomized Phase III Trial Comparing Biweekly Infusional Fluorouracil/Leucovorin Alone or With Irinotecan in the Adjuvant Treatment of Stage III Colon Cancer: PETACC-3. <i>Journal of Clinical Oncology</i> , 2009, 27, 3117-3125.	1.6	437

#	ARTICLE	IF	CITATIONS
73	Basics in clinical nutrition: Complications of enteral nutrition. European E-journal of Clinical Nutrition and Metabolism, 2009, 4, e209-e211.	0.4	9
74	A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. European Journal of Cancer, 2009, 45, 1589-1596.	2.8	66
75	Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer. New England Journal of Medicine, 2009, 360, 1408-1417.	27.0	3,543
76	Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): Secondary and subset analyses. Journal of Clinical Oncology, 2009, 27, 4511-4511.	1.6	24
77	CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncology, The, 2008, 9, 132-138.	10.7	210
78	Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trialâ€”SAKK 44/00â€”CECOG/PAN.1.3.001. Journal of Clinical Oncology, 2008, 26, 3695-3701.	1.6	93
79	Oxaliplatin Plus Irinotecan Compared With Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. Journal of Clinical Oncology, 2008, 26, 4544-4550.	1.6	55
80	Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. British Journal of Cancer, 2007, 97, 1469-1474.	6.4	77
81	Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology, 2007, 25, 2212-2217.	1.6	543
82	3013 ORAL Tissue biomarkers in colon cancer (COC): Early results of the translational study on a phase III trial comparing infused irinotecan/ 5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage IIâ€”III COC patients (PETACC 3â€”EORTC 40993â€”SAKK 60/00). European Journal of Cancer, Supplement, 2007, 5, 239.	2.2	2
83	ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clinical Nutrition, 2006, 25, 245-259.	5.0	665
84	Randomized, Double-Blind, Active-Controlled Trial of Every-3-Week Darbepoetin Alfa for the Treatment of Chemotherapy-Induced Anemia. Journal of the National Cancer Institute, 2006, 98, 273-284.	6.3	97
85	Final results of a randomized, double-blind, active-controlled trial of darbepoetin alfa administered once every 3 weeks (Q3W) for the treatment of anemia in patients receiving multicycle chemotherapy. Journal of Clinical Oncology, 2005, 23, LBA8284-LBA8284.	1.6	11
86	Effect of Dose Reductions on Response to 500-Î¼g Darbepoetin alfa Administered Once Every 3 Weeks for the Treatment of Chemotherapy-Induced Anemia: Analysis from a Randomized, Double-Blind, Active-Controlled Trial.. Blood, 2005, 106, 3558-3558.	1.4	0
87	Rectal Cancer Therapy: Decision Making on Basis of Quality of Life?. Zentralblatt Fur Chirurgie, 2004, 129, 139-148.	0.3	15
88	Ileocolic Anastomotic Ulcer after Surgery in Adulthood: Case Report and Review of the Literature. Zeitschrift Fur Gastroenterologie, 2004, 42, 605-608.	0.5	8
89	The efficacy of a combination of etoposide, ifosfamide, and cisplatin in the treatment of patients with soft tissue sarcoma. Cancer, 2000, 89, 177-80.	4.1	7
90	State of artificial nutrition in Hungary: standpoint and methodologic recommendations. Nutrition, 1999, 15, 40-43.	2.4	5

#	ARTICLE	IF	CITATIONS
91	Effects of different types of isocaloric parenteral nutrients on food intake and metabolic concomitants. <i>Physiology and Behavior</i> , 1995, 58, 75-79.	2.1	9
92	Effects of fasting, intermittent feeding, or continuous parenteral nutrition on rat liver and brain energy metabolism as assessed by ³¹ P-NMR. <i>Physiology and Behavior</i> , 1995, 58, 521-527.	2.1	16
93	Nocturnal cyclic versus continuous total parenteral nutrition: Food intake and feeding pattern in rats. <i>Physiology and Behavior</i> , 1992, 51, 431-435.	2.1	7
94	The comparative effects of abrupt vs. stepwise discontinuation of TPN in rats. <i>Physiology and Behavior</i> , 1992, 52, 591-595.	2.1	3
95	The effect of jejunal nutrition on pancreatic exocrine function. <i>Acta Chirurgica Hungarica</i> , 1992, 33, 13-21.	0.0	4
96	The effect of early postoperative nutrition on exocrine pancreatic function. <i>Acta Chirurgica Hungarica</i> , 1992, 33, 23-35.	0.0	2
97	Effect of enteral nutrition on exocrine pancreatic function. <i>American Journal of Surgery</i> , 1991, 161, 144-148.	1.8	79
98	The method of early postoperative alimentation by needle-catheter jejunostomy. <i>Acta Chirurgica Hungarica</i> , 1989, 30, 55-61.	0.0	1
99	An up-to-date method of early postoperative enteral feeding. <i>Acta Paediatrica Hungarica</i> , 1987, 28, 51-7.	0.0	0